Approximately 360 million people (6% of the world’s population) are chronically infected with the hepatitis B virus worldwide. Although the rate of hepatitis B infection has decreased dramatically with the widespread availability and implementation of hepatitis B vaccination programs in many countries and rigorous screening of blood donors, large numbers of children continue to be infected with the hepatitis B virus each year. About 30% to 50% of the hepatitis B virus infected in childhood will turn into chronic viral hepatitis B in the years when they grow into adults, and about 3% to 5% will develop cirrhosis and 0.01% to 0.03% will develop liver cancer before they become adults. Currently, the goal of international anti-hepatitis B treatment is to improve long-term survival and quality of life by reducing the risk of liver disease progression, cirrhosis and liver cancer. The most desirable treatment endpoints are sustained negative hepatitis B surface antigen, positive hepatitis B surface antibody, and hepatitis B virus clearance! This is because this halts disease progression and reduces the risk of liver cancer. However, this ideal endpoint occurs only in a very small number of treated patients, and of the 17 children with chronic hepatitis B viral hepatitis treated at our hospital, two have fully achieved this optimal goal, and six others have also achieved the international secondary goal of converting from hepatitis B “major triple-positive” to “minor triple-positive”, with undetectable hepatitis B viral DNA. The quantitative analysis of the hepatitis B manifestation antigen decreased significantly, and it is also possible to finally reach the desired goal. Safe and effective antiviral treatment regimens are available for chronic viral hepatitis B in adults, but very few drugs are approved for the treatment of hepatitis B in children. A limited course of interferon alfa antiviral therapy is extremely the primary choice in the international strategy for the treatment of hepatitis B in children. Interferon alfa is the only currently available drug that allows patients to sustain response after discontinuation of the drug. It has been found through research that hepatitis B virus infection in childhood is more likely to lead to chronic hepatitis B viral hepatitis than in adulthood, and the reason for this is related to incomplete immune function in childhood, regarding the regulation of immune function may be another important strategy for the treatment of hepatitis B. Chinese medicine in China has its unique advantage in regulating immune capacity, and the combination of the two treatments has had the desired effect. The possibility of healing hepatitis B viral hepatitis, bringing summer light to hepatitis B patients!